ArticleWorld journal of cardiology2025
Prognostic impact of prediabetic glycated hemoglobin levels in nondiabetic patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
Article in World journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlycated hemoglobin (HbA1c) is a well-established biomarker for diagnosing and managing diabetes. However, its prognostic significance in patients without diagnosed diabetes undergoing percutaneous coronary intervention (PCI) remains uncertain. This systematic review and meta-analysis evaluates the association between elevated HbA1c levels in the prediabetic range (≥ 5.7%) and adverse cardiovascular outcomes in this population.
aimTo investigate the association between elevated HbA1c levels in the prediabetic range and adverse outcomes in patients without diagnosed diabetes undergoing PCI.
methodsWe systematically searched PubMed, EMBASE, and Cochrane Central through April 2025 for studies comparing clinical outcomes in coronary artery disease (CAD) patients without a prior diabetes diagnosis, stratified by HbA1c levels (≥ 5.7%
resultsTen studies involving 32403 patients (mean age: 60 years; 29% female) were included. Elevated HbA1c levels in patients without diagnosed diabetes were significantly associated with increased risk of long-term all-cause mortality (RR: 1.30; 95%CI: 1.10-1.54;
conclusionAmong CAD patients without diagnosed diabetes, elevated HbA1c levels in the prediabetic range (≥ 5.7%) are independently associated with worse long-term outcomes following PCI. HbA1c may serve as a valuable biomarker for post-PCI risk stratification in this metabolically at-risk group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.